Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Pfizer (NYSE:PFE) with a Underperform ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following ...

On Friday, Hess Corp (HES) stock saw a modest uptick, ending the day at $145.64 which represents a slight increase of $0.58 or 0.40% from the prior close of $145.06. The stock opened at $144.67 and ...

On Friday, Fifth Third Bancorp (FITB) stock saw a decline, ending the day at $46.99 which represents a decrease of $-0.27 or -0.57% from the prior close of $47.26. The stock opened at $47.51 and ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ: NASDAQ: WBD) to Peer Perform from ...

Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (LSE:0HD2) from Peer Perform to Underperform. There are 1,155 funds or institutions ...